Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004)

NCT04373460 PHASE2 COMPLETED Results posted

To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.

Details

Lead sponsor	Johns Hopkins University
Phase	PHASE2
Status	COMPLETED
Enrolment	1225
Start date	Wed Jun 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• SARS-CoV 2

Interventions

• SARS-CoV-2 convalescent plasma
• Plasma from a volunteer donor

Countries

United States